Document Detail


Ximelagatran: an orally active direct thrombin inhibitor.
MedLine Citation:
PMID:  15998925     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, contraindications, and adverse effects of ximelagatran are reviewed. SUMMARY: Ximelagatran is the first orally active direct thrombin inhibitor to be tested in Phase III clinical trials. After oral administration, ximelagatran is rapidly converted to its active metabolite, melagatran. Melagatran (after oral ximelagatran administration) predictably inhibits thrombin function without need for routine anticoagulation monitoring. Melagatran effectively inhibits both free and clot-bound thrombin-a potential pharmacodynamic advantage over heparin products. Melagatran has a half-life of 2.4-4.6 hours, necessitating twice-daily administration. Melagatran is primarily eliminated by the kidneys and has not been studied clinically in patients with severe renal failure. Ximelagatran has undergone 10 Phase III trials (6 for prophylaxis of venous thromboembolism [VTE] due to orthopedic surgery, 1 for initial treatment of VTE, 1 for long-term prevention of VTE recurrence, and 2 for stroke prophylaxis due to atrial fibrillation). Results were generally positive. AstraZeneca applied in December 2003 for marketing approval of ximelagatran for prevention of VTE after total knee replacement surgery, long-term prevention of VTE recurrence after standard therapy, and stroke prevention due to atrial fibrillation. FDA denied approval of ximelagatran for all indications, mainly because of increased rates of coronary artery disease events in ximelagatran recipients in some studies and the possibility of hepatic failure when the medication is used for long-term therapy. CONCLUSION: Ximelagatran has shown promise as a possible alternative to warfarin and other anticoagulants but will require further study to ensure its safety.
Authors:
Michael P Gulseth
Related Documents :
7942465 - International experience with secundum atrial septal defect occlusion by the buttoned d...
24271325 - Natural history of pulmonary function in collagen vi-related myopathies.
10869265 - Mapping and ablation of left atrial flutters.
12390055 - Ibutilide in rapid conversion of atrial flutter in octogenarians.
17056365 - Static otolith-ocular reflex reflects superior oblique muscle disorder.
10731275 - Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a hist...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  62     ISSN:  1079-2082     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-07-06     Completed Date:  2005-11-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1451-67     Citation Subset:  IM    
Affiliation:
University of Minnesota College of Pharmacy/Saint Mary's Medical Center, 344 Kirby Plaza, 1208 Kirby Drive, Duluth, MN 55812, USA. mgulseth@umn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / adverse effects,  pharmacokinetics,  therapeutic use*
Atrial Fibrillation / complications
Azetidines / adverse effects,  pharmacokinetics,  therapeutic use*
Benzylamines
Biological Availability
Clinical Trials, Phase III as Topic
Drug Interactions
Half-Life
Humans
Metabolic Clearance Rate
Stroke / etiology,  prevention & control
Thrombin / antagonists & inhibitors*
Thromboembolism / prevention & control
Venous Thrombosis / prevention & control
Warfarin / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Azetidines; 0/Benzylamines; 0/ximelagatran; 81-81-2/Warfarin; EC 3.4.21.5/Thrombin
Comments/Corrections
Comment In:
Am J Health Syst Pharm. 2005 Jul 15;62(14):1449   [PMID:  15998924 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The MicrobesOnline Web site for comparative genomics.
Next Document:  Association between short-term effectiveness of statins and long-term adherence to lipid-lowering th...